Showing results (51-60 of 60) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Frontiers in Pharmacology|November 5, 2019
2-APB and CBD-Mediated Targeting of Charged Cytotoxic Compounds Into Tumor Cells Suggests the Involvement of TRPV2 ChannelsHagit Neumann-Raizel, Asaf Shilo, Shaya Lev, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|April 15, 2015
A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic indexAnna Scomparin, Stefano Salmaso, Anat Eldar-Boock, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|November 16, 2018
In Vivo PET Tracking of 89Zr-Labeled Vγ9Vδ2 T Cells to Mouse Xenograft Breast Tumors Activated with Liposomal AlendronateFrancis Man, Lindsay Lim, Alessia Volpe, et al.Journal of Gastrointestinal Cancer|August 17, 2010
A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinomaMaeve Lowery, Manish A Shah, Elizabeth Smyth, et al.Molecular Cancer Therapeutics|August 13, 2011
BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicinTamar Safra, Lucia Borgato, Maria Ornella Nicoletto, et al.International Journal of Pharmaceutics|May 6, 2017
Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugsAndrew T Lucas, Leah B Herity, Zack A Kornblum, et al.ACS Nano|October 27, 2016
Exploiting the Metal-Chelating Properties of the Drug Cargo for In Vivo Positron Emission Tomography Imaging of Liposomal NanomedicinesScott Edmonds, Alessia Volpe, Hilary Shmeeda, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 24, 2014
Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acidAna C Parente-Pereira, Hilary Shmeeda, Lynsey M Whilding, et al.ACS Nano|January 10, 2017
Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for SolutionsThomas J Anchordoquy, Yechezkel Barenholz, Diana Boraschi, et al.ACS Nano|May 20, 2024
Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future DirectionsThomas Anchordoquy, Natalie Artzi, Irina V Balyasnikova, et al.Pageof 6